AbbVie Reports First-Quarter 2024 Financial Results : vimars

Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These...

Related Keywords

United States , American , Alphagan Combigan , Roberta Michael , Linzess Constella , Lumigan Ganfort , Richarda Gonzalez , Landos Biopharma , Tentarix Biotherapeutics , Drug Administration , American Academy Of Neurology , Twitter , Allergan , European Medicines Agency , Colitis Organisation , American Academy Of Dermatology , Boehringer Ingelheim , Abbvie Inc , Exchange Commission , Reports First Quarter Diluted , Adjusted Diluted , These Results Include , Unfavorable Impact , Share Related , First Quarter Net Revenues , Reported Basis , Quarter Global Net Revenues , Immunology Portfolio Were , Operational Basis , Humira Biosimilar Competition , Global Humira Net Revenues Were , Global Skyrizi Net Revenues Were , Global Rinvoq Net Revenues Were , Oncology Portfolio Were , Global Imbruvica Net Revenues Were , Global Venclexta Net Revenues Were , Neuroscience Portfolio Were , Global Botox Therapeutic Net Revenues Were , Global Vraylar Net Revenues Were , Combined Global Ubrelvy , Qulipta Net Revenues Were , Aesthetics Portfolio Were , Global Botox Cosmetic Net Revenues Were , Global Juvederm Net Revenues Were , Completed Acquisition , Flagship Cancer Therapy , Milestones Expense Incurred During , First Quarter , Botox Therapeutic , Botox Cosmetic , Priority Review , Biologics License Application , Breakthrough Therapy Designation , Eczema Area , Severity Index , Worst Pruritus Numerical Rating Scale , European Crohn , Annual Meeting , Allergan Aesthetic , Juvederm Voluma , American Academy , Allergan Aesthetics , Investor Relations , Private Securities Litigation Reform Act , Cerevel Therapeutics , Quarterly Reports , Ended March ,